Be Clinical, a skincare brand, has raised ₹6 crore in its seed funding round led by V3 Ventures, with participation from Titan Capital.
The fresh capital raised will be used for research and development to strengthen in-house formulation capabilities, conduct clinical testing, and develop targeted solutions for ageing concerns across the face, body, and scalp.
In May 2025, Be Clinical raised ₹2 crore in seed funding round led by Titan Capital, with participation from P-TAL founder Aditya Agarwal.
The company will also expand its manufacturing facility by adding advanced machinery to improve production capacity, consistency, and quality control. In addition, part of the funding will be used to upgrade packaging with functional, protective, and premium formats that preserve ingredient efficacy while reinforcing the brand’s clinical-grade positioning.
Founded in May 2025 by Hemangi Dhir, Be Clinical is a science-driven skincare brand that specializes in developing clinically tested, anti-aging solutions using medical-grade formulations. The brand focuses on transparency, efficacy, and results-driven products for the modern consumer.
While much of the category is driven by marketing claims or inaccessible clinical treatments, Be Clinical differentiates itself through in-vivo tested, clinically validated formulations, supported by end-to-end in-house research and manufacturing and responsible formulation.
As of December 31, 2025, the brand claims to have served over 25,000 customers.
Hemangi Dhir, Founder, Be Clinical, said, “This moment feels incredibly special for us. The continued support from our existing investors, along with the partnership with V3 Ventures and Titan Capital, gives us strong conviction as we enter our next phase of growth. At Be Clinical, we are deeply committed to honest skincare — where evidence leads, trust is earned, and ageing is addressed with clarity, confidence, and care.”
Arjun Vaidya, Co-Founder at V3 Ventures, said, “At V3, we are seeing a big change in the beauty and personal care space. Customers have moved from being generalists to knowledgeable and specific. We believe anti-aging is a massive, untapped space that starts seeing relevance in a consumer’s mind mid 20s. We loved Hemangi’s vision, depth of product knowledge and in-house manufacturing prowess. This is what drew us to back the venture early, and we are really excited for what’s ahead.”
“We are happy to back Be Clinical again. We backed Hemangi because she is solving a real problem with a product-led, science-driven approach. The company has stayed focused on building formulations that work, not on chasing trends. As the company scales, that clarity of thinking and discipline around the product is what gives us confidence in their long-term potential,” said a spokesperson at Titan Capital.
